ZA201105755B - Combination therapies for neoplastic disorders - Google Patents

Combination therapies for neoplastic disorders

Info

Publication number
ZA201105755B
ZA201105755B ZA2011/05755A ZA201105755A ZA201105755B ZA 201105755 B ZA201105755 B ZA 201105755B ZA 2011/05755 A ZA2011/05755 A ZA 2011/05755A ZA 201105755 A ZA201105755 A ZA 201105755A ZA 201105755 B ZA201105755 B ZA 201105755B
Authority
ZA
South Africa
Prior art keywords
combination therapies
neoplastic disorders
neoplastic
disorders
therapies
Prior art date
Application number
ZA2011/05755A
Inventor
Denis Drygin
Joshua R Bliesath
Sean O'brien
Caroline B Ho
Christopher B Proffitt
Kenna Anderes
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of ZA201105755B publication Critical patent/ZA201105755B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA2011/05755A 2009-01-08 2011-08-04 Combination therapies for neoplastic disorders ZA201105755B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14328209P 2009-01-08 2009-01-08
PCT/US2009/046948 WO2010080170A1 (en) 2009-01-08 2009-06-10 Combination therapies for neoplastic disorders

Publications (1)

Publication Number Publication Date
ZA201105755B true ZA201105755B (en) 2012-04-25

Family

ID=40973134

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/05755A ZA201105755B (en) 2009-01-08 2011-08-04 Combination therapies for neoplastic disorders

Country Status (13)

Country Link
EP (1) EP2381942A1 (en)
JP (1) JP2012514638A (en)
KR (1) KR20110116153A (en)
CN (1) CN102341107A (en)
AU (1) AU2009336141A1 (en)
BR (1) BRPI0924041A2 (en)
CA (1) CA2749261A1 (en)
IL (1) IL213969A0 (en)
MX (1) MX2011007384A (en)
RU (1) RU2011133093A (en)
SG (1) SG172922A1 (en)
WO (1) WO2010080170A1 (en)
ZA (1) ZA201105755B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
KR20210079313A (en) * 2018-10-19 2021-06-29 센화 바이오사이언시즈 인코포레이티드 Combinations for Immunomodulation in Cancer Treatment
CN114869903A (en) * 2022-06-14 2022-08-09 苏天生命科技(苏州)有限公司 Application of bafilomycin A1 in optimization of acute gonorrhea leukemia chemotherapy combination drug

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5399905B2 (en) * 2006-09-01 2014-01-29 センワ バイオサイエンシズ インコーポレイテッド Serine-threonine protein kinase and PARP regulator
CA2683804A1 (en) * 2007-04-13 2008-10-23 Dana Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling

Also Published As

Publication number Publication date
RU2011133093A (en) 2013-02-20
IL213969A0 (en) 2011-08-31
KR20110116153A (en) 2011-10-25
CN102341107A (en) 2012-02-01
JP2012514638A (en) 2012-06-28
BRPI0924041A2 (en) 2016-01-26
SG172922A1 (en) 2011-08-29
AU2009336141A1 (en) 2011-08-11
WO2010080170A1 (en) 2010-07-15
MX2011007384A (en) 2011-12-14
CA2749261A1 (en) 2010-07-15
EP2381942A1 (en) 2011-11-02

Similar Documents

Publication Publication Date Title
HRP20181423T1 (en) Gene therapy for neurodegenerative disorders
HUS1800001I1 (en) Combination therapy for COPD
ZA201203342B (en) Treatments for gastrointestinal disorders
EP2485727A4 (en) Pyrrolopyrazoles for treating cns disorders
EP2271358A4 (en) Neurodegenerative disorders
HK1174571A1 (en) Combination therapy for copd copd
PL2536742T3 (en) Treatments for gastrointestinal disorders
ZA201202346B (en) Therapeutic agent for mood disorders
ZA201105755B (en) Combination therapies for neoplastic disorders
IL207906A0 (en) Treatment for ocular-related disorders
GB201306866D0 (en) Neurodegenerative Disorders
GB0918626D0 (en) Therspeutics for neurological disorders
GB0915543D0 (en) Nasal therapies for CNS conditions